Stay updated on Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check6 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.1 to v3.7.2; the page continues to display a 403 error.SummaryDifference0.2%

- Check13 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedA 403 Forbidden page is now displayed for the study record NCT03955471, replacing the previously visible study details and navigation. This indicates the page is blocked or failing to load, preventing access to the study information.SummaryDifference20%

- Check55 days agoChange DetectedThe page's revision label changed from v3.6.5 to v3.6.6, reflecting a minor version update to the page. This does not alter the study information or how the page operates.SummaryDifference0.0%

- Check77 days agoChange DetectedThe page's revision label shows v3.6.5, replacing v3.6.4. This indicates a small metadata update to the page revision history without changing the study content.SummaryDifference0.0%

- Check91 days agoChange DetectedA new revision tag, v3.6.4, has been added to replace the previous v3.6.3, signaling a minor site deployment update rather than changes to the study information.SummaryDifference0.0%

Stay in the know with updates to Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.